1. Home
  2. CPRI vs KOD Comparison

CPRI vs KOD Comparison

Compare CPRI & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capri Holdings Limited

CPRI

Capri Holdings Limited

HOLD

Current Price

$18.27

Market Cap

2.4B

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$33.22

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPRI
KOD
Founded
1981
2009
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.3B
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
CPRI
KOD
Price
$18.27
$33.22
Analyst Decision
Buy
Buy
Analyst Count
13
7
Target Price
$26.62
$35.43
AVG Volume (30 Days)
3.2M
551.3K
Earning Date
05-27-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
111.40
N/A
EPS
1.14
N/A
Revenue
$3,474,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.81
N/A
P/E Ratio
$16.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.49
$3.43
52 Week High
$28.27
$47.84

Technical Indicators

Market Signals
Indicator
CPRI
KOD
Relative Strength Index (RSI) 47.27 38.27
Support Level $16.82 $32.93
Resistance Level $22.24 $46.72
Average True Range (ATR) 0.89 2.28
MACD 0.11 -0.34
Stochastic Oscillator 41.86 14.38

Price Performance

Historical Comparison
CPRI
KOD

About CPRI Capri Holdings Limited

Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: